ArticleMicrobial cell factories2026
Exploitation of actinomycetes from coastal ecosystems of İzmir Peninsula for antimicrobial activity via strain identification, untargeted metabolomics and drug combination studies.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAntimicrobial resistance poses a major global health threat, highlighting the urgent need for novel bioactive compounds. Actinomycetes in the phylum Actinomycetota are prolific producers of antimicrobial agents; however, marine-derived strains remain underexplored, despite their ecological diversity and biosynthetic potential. In this study, we investigated the antimicrobial properties of Actinomycetes isolated from coastal sediments of İzmir Peninsula, situated on the Aegean Sea.
resultsOur extensive isolation efforts yielded 945 strains from 46 sediment samples. Overall, 38% of their extracts exhibited antibacterial or antifungal activity against at least one of the tested human pathogens. Based on prominent activities and chemical richness, fifteen potent extracts were selected for metabolomics, strain identification, and drug combination studies. MS²-based dereplication studies identified known antimicrobials, including chromomycin A3, leucomycin A1, actinomycin D, K-41 A, collismycin A, desferrioxamine E, terragine E, tirandamycin A, bafilomycin C1, and their derivatives, as well as chloramphenicol, lauramine-oxide, and staurosporine. Molecular networks of potent extracts reveal the potential of unidentified metabolites through node clustering. Also, strain identification studies have proven that all potent isolates belong to the genus Streptomyces. Notably, two extracts (involving leucomycin A1 or K-41 A) demonstrated strong synergy with oxacillin against MRSA, while three extracts (containing staurosporine or bafilomycin C1) showed agonist effects with fluconazole against resistant Candida albicans, indicating potential for combination therapy.
conclusionThis study highlights the marine-derived Streptomyces from the Aegean coasts as a promising resource for the discovery of antimicrobial agents against resistant pathogens. Further bioactivity-guided isolation studies are ongoing to characterize the active constituents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.